BridgeBio Pharma Discounted Cash Flow

BridgeBio Pharma (BBIO) currently reports a DCF fair value of $-77. Use the charts on this page to explore BridgeBio Pharma's DCF fair value history and peer comparisons.

BridgeBio Pharma's discounted cash flow (DCF) fair value estimate is $-77, about 210.9% overvalued versus the current market price. DCF models project future free cash flows and discount them back to today — so the result depends on growth, margin, and discount-rate assumptions. Use it as one valuation lens alongside multiples and peer checks on Stockcircle.

Start with the current DCF fair value of $-77, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for BridgeBio Pharma, and consider following BBIO for alerts when major investors trade the stock.

BridgeBio Pharma is classified in the Healthcare sector. On DCF fair value, it currently shows $-77. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BBIO with unrelated industries.